- Brand name: Keytruda
- Active Ingeridents(Generic Name) : Pembrolizumab
- Company Name: Merck
- Package: Vial
- Strength: 50mg
Before using Keytruda (Pembrolizumab), tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.
Store at room temperature, away from heat, moisture, Keep out of the reach of children. Do not keep outdated medicine or medicine no longer needed.
Keytruda (Pembrolizumab) is used to treat certain types of cancers (skin cancer, non-small cell lung cancer). It works by changing the action of your own immune system, directing it to attack cancer cells. Keytruda (Pembrolizumab) belongs to a class of drugs known as monoclonal antibodies.
Mechanism of action:
Keytruda (Pembrolizumab) is an antibody drug that targets the cell surface receptor programmed cell death protein 1 (PD-1) found on T cells. By preventing the binding of its ligands (PD-L1 and PD-L2), Keytruda (Pembrolizumab) induces an antitumor immune response. Upregulation of PD-1 ligands is a mechanism for tumours to evade antitumor immune response; when PD-1 binds its ligand, the T cell receives an inhibitory signal leading to T cell anergy and blockade of anti tumour immune response. Instead of directly targeting tumor tissue to induce tumor cell death, Keytruda (Pembrolizumab) acts as a checkpoint inhibitor to stimulate immune responses to eliminate cancer cells.
Dosage and Administration:
Keytruda (Pembrolizumab) is given as an intravenous injection through a vein (IV) over 30 minutes every 3 weeks.
You may receive medications before the infusion to reduce allergic reactions.
The amount of Keytruda (Pembrolizumab) that you will receive depends on many factors, including your weight, your general health or other health problems, and the type of cancer or condition being treated. Your doctor will determine your dose and schedule.
The following side effects are common (occurring in greater than 30%) for patients taking Keytruda (Pembrolizumab):
Anemia ,Fatigue, Hyperglycemia, Hyponatremia, Hypoalbuminemia, Itching, Cough, Nausea
These side effects are less common side effects (occurring in about 10-29%) of patients receiving Keytruda (Pembrolizumab):
Rash, Decreased appetite, Hypertriglyceridemia, Increased liver enzymes, Hypocalcemia, Constipation, Diarrhea, Arthralgia, Pain in extremity, Shortness of breath, Swelling, Headache, Vomiting, Chills, Myalgia, Insomnia, Abdominal pain, Back pain, Fever, Vitiligo, Dizziness, Upper respiratory tract infection
- As Per Order Requirement Per Day
- 1-12 Days
Portion A, First Floor, Old No. 131, New No. 50, Pedariyar Koil Street, Seven Wells Chennai Tamil Nadu India +918045478353